We performed our investigation using the human PIK3CA mutant colorectal carcinoma HT29 and PTEN null prostate carcinoma PC3 cancer models as AKT signalling is involved in the tumourigenesis of colorectal and prostate cancers and AKT inhibitors are in clinical evaluation for both cancer types.37–39. This evidence concerns the gene AKT1 and prostate carcinoma.